Current perspectives in the recognition and management of psoriatic arthritis: Implications for integrated patient care

American Journal of Managed Care

Volumn 8, Issue 6 SUPPL., 2002, Pages

  Ruderman, Eric M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CYCLOSPORIN; CYTOKINE; ETANERCEPT; GOLD SALT; METHOTREXATE; PENICILLAMINE; RECOMBINANT TUMOR NECROSIS FACTOR; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG;

CLINICAL FEATURE; CLINICAL TRIAL; CYTOKINE RELEASE; DISEASE COURSE; DRUG APPROVAL; DRUG TOLERABILITY; DRUG WITHDRAWAL; FACTORIAL ANALYSIS; HUMAN; JOINT EXAMINATION; LONG TERM CARE; MORBIDITY; MORTALITY; PATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SPONDYLOARTHROPATHY;

ANTI-INFLAMMATORY AGENTS; ARTHRITIS, PSORIATIC; DELIVERY OF HEALTH CARE, INTEGRATED; DISEASE PROGRESSION; HEALTH STATUS; HUMANS; PROGNOSIS; QUALITY OF LIFE; UNITED STATES;

EID: 0036345504     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Psoriasis
2. Association between rheumatoid arthritis and psoriasis in total populations
3. New research shows 1 million US adults suffer from psoriatic arthritis. Others may be at risk but not know it
4. Psoriatic arthritis
5. Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondyloarthropathy
6. Classification of inflammatory arthritis by enthesitis
7. Psoriatic arthritis (PA): A clinical, immunological, and radiological study of 180 patients
8. Psoriatic arthritis (PsA) - An analysis of 220 patients
9. Mortality studies in psoriatic arthritis. Results from a single outpatient center. II. Prognostic indicators for death
10. Mortality studies in psoriatic arthritis. Results from a single outpatient clinic. I. Causes and risk of death
11. Psoriatic arthritis
12. Associations between ankylosing spondylitis, psoriatic arthritis, Reiter's disease, the intestinal arthropathies and Behçet's syndrome
13. Longitudinal study of clinical and radiological progression in psoriatic arthritis
14. Psoriatic arthritis: Outcome of disease subsets and relationship of joint disease to nail and skin disease
15. Validating the SF-36 health questionnaire in patients with psoriatic arthritis
16. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection
17. Measuring health status in arthritis: The Arthritis Impact Measurement Scales
18. AIMS2. The content and properties of a revised and expanded Arthritis Impact Measurement Scales health status questionnaire
19. Performance of the Norwegian SF-36 health survey in patients with rheumatoid arthritis. II. A comparison of the SF-36 with disease-specific measures
20. Use of the short form 36 (SF-36) for health status measurement in rheumatoid arthritis
21. Measuring health status in British patients with rheumatoid arthritis: Reliability, validity, and responsiveness of the short form 36-item health survey (SF-36)
22. Responsiveness of health status instruments to changes in articular status and perceived health in patients with psoriatic arthritis
23. Health-related quality of life of patients with psoriatic arthritis: A comparison with patients with rheumatoid arthritis
24. Development of an upper extremity outcome measure: The DASH (disabilities of the arm, shoulder, and hand)
25. Validity assessment of the Disabilities of Arm, Shoulder, and Hand Questionnaire (DASH) for patients with psoriatic arthritis
26. Familiar occurrence of psoriatic arthritis
27. Psoriatic arthritis. A unified concept twenty years on
28. A reevaluation of the osteoarticular manifestations of psoriasis
29. Progression of psoriatic arthritis: Role of time varying clinical indicators
30. Clinical indicators of progression in psoriatic arthritis: Multivariate relative risk model
31. The role of HLA antigens as indicators of disease progression in psoriatic arthritis. Multivariate relative risk model
32. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study
33. Sulphasalazine in psoriatic arthritis: A randomized, multicentre, placebo-controlled study
34. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study
35. Randomized, double-blind, placebo-controlled trial of low-dose pulse methotrexate in psoriatic arthritis
36. Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: A one-year prospective study
37. Methotrexate and cyclosporin combined therapy in severe psoriatic arthritis. A pilot study
38. Adverse drug reactions of DMARDs and DC-ARTS in rheumatoid arthritis
39. Are the results of controlled clinical trials and observational studies of second line therapy valid and generalizable as measures of rheumatoid arthritis outcome: Analysis of 122 studies
40. Long-term treatment of destructive rheumatoid arthritis with methotrexate
41. Highly increased levels of tumor necrosis factor-α and other proinflammatory cytokines in psoriatic arthritis synovial fluid
42. Upregulation of cytokine receptors sTNF-R55, sTNF-R75, and sIL-2R in psoriatic arthritis synovial fluid
43. Patterns of cytokine production in psoriatic synovium
44. Elevated tumour necrosis factor-alpha (TNF-α) biological activity in psoriatic skin lesions
45. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
46. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial
47. Long-term use of etanercept in DMARD-refractory rheumatoid arthritis
48. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
49. Long-term safety and efficacy of combination therapy with methotrexate (MTX) and etanercept (Enbrel)
50. A phase III trial of etanercept vs methotrexate (MTX) in early rheumatoid arthritis (Enbrel ERA trial)
51. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial
52. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis
53. American college of rheumatology preliminary definition of improvement in rheumatoid arthritis
54. Severe psoriasis - Oral therapy with a new retinoid
55. Enbrel (etanercept) in patients with psoriatic arthritis and psoriasis